Respiratory syncytial virus – Page 3

GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.

FDA Expands Approval of GSK’s RSV Vaccine to Include At-Risk Adults Aged 50-59

11 months ago talkbio0Tagged Adult, Approved, Arexvy, At-Risk, Respiratory syncytial virus, Respiratory Syncytial Virus Vaccines, SmithKline Beecham, United States Food and Drug Administration

RSV vaccine, GSK, FDA approval, at-risk adults, respiratory syncytial virus, Arexvy

FDA Approves Moderna’s RSV Vaccine, Marking Its Second Commercial Product

11 months ago talkbio0Tagged Approved, COVID19 (disease), Moderna, mRESVIA, Respiratory syncytial virus, RNA, Messenger, Spikevax, United States Food and Drug Administration, Vaccines

Moderna, RSV Vaccine, FDA Approval, mRNA Technology, Respiratory Syncytial Virus, COVID-19, Spikevax, mRESVIA

Moderna’s Diversification Strategy Hindered by FDA Delay in RSV Vaccine Review

12 months ago talkbio0Tagged Moderna, Respiratory syncytial virus, United States Food and Drug Administration, vaccine review, Vaccines

Moderna, FDA, RSV vaccine, diversification strategy, vaccine review, delay

Moderna’s RSV Vaccine Decision Postponed by FDA to Late May

12 months ago talkbio0Tagged Decision, May, Moderna, Respiratory syncytial virus, United States Food and Drug Administration, Vaccines

FDA, Moderna, RSV vaccine, decision, delay, May

GSK confirms Arexvy is a blockbuster but says the RSV battle has just begun

1 year ago talkbio0Tagged Arexvy, battle, begun, Respiratory syncytial virus

Arexvy, Respiratory syncytial virus, battle, begun